Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

RGNX Stock On Track For Worst Day In Over Three Months — BofA Says Buy Despite ...

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at es.tradingview.com →

◆ Verified

Fusion42 · 25 August 2026 · Fusion42 review

Regenxbio's gene therapy RGX-121 faced a clinical hold by the FDA due to unexpected spinal growths in treated patients, causing a significant stock drop despite Bank of America maintaining a Buy rating based on other promising programs.

This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it.

◆ ◆ The Wire takeaway

Your biotech venture just hit a regulatory roadblock that revalues risk for gene therapy investors. Review your portfolio exposure and accelerate communications around unaffected programs to maintain investor confidence.

◆ Coverage

6 sources · 24 Aug 2026

◆ Related on Wire

◆ Topics

Biotechgene-therapyfda-holdclinical-trialbiotech-stockregulatory-setback